Loading
A phase 2 trial of REC-4881 run by Recursion Pharmaceuticals Inc., terminated.
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation is a phase 2 interventional study registered as NCT06005974 by Recursion Pharmaceuticals Inc., with 18 participants enrolled, started 2024-01-15. Conditions recorded: AXIN1 Gene Mutation, APC Gene Mutation and Solid Tumor. Interventions recorded: REC-4881.
Shares REC-4881, Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Recursion Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Recursion Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Recursion Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals and the tag pipeline.
Shares Recursion Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/